Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022–2023

Emerging infectious diseases 2026 Open access

Read full text
Authors: Jessica Laury, Kaitlin Forsberg, Elizabeth L. Berkow, Sophie Jones, D. Joseph Sexton, Dawn Sievert, Shawn R. Lockhart, Jeremy A.W. Gold, Meghan Lyman
DOI: 10.3201/eid3202.251043
Cited by: 9
References: 8

Abstract

During 2022-2023, the Antimicrobial Resistance Laboratory Network tested 8,033 Candida auris clinical isolates in the United States. Overall, 95% of isolates were fluconazole resistant, 15% amphotericin B resistant, and 1% echinocandin resistant. Laboratory capacity for C. auris identification and antifungal susceptibility testing is essential to address this emerging public health threat.

Fields of Study & Subjects

Antifungal resistance and susceptibility Fungal Infections and Studies Reproductive tract infections research

Publication details

Journal / source
Emerging infectious diseases
Publisher
Centers for Disease Control and Prevention (CDC)
Volume
32
Issue
2
Pages
308–310
Publication date
1 February 2026
Language
EN